Page last updated: 2024-10-27

fluorouracil and Carcinoma, Transitional Cell

fluorouracil has been researched along with Carcinoma, Transitional Cell in 165 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.

Research Excerpts

ExcerptRelevanceReference
"We assessed effectiveness, safety, and tolerability of paclitaxel or fluorouracil when added to radiation plus cisplatin followed by adjuvant chemotherapy in a programme of selected bladder preservation for patients with muscle invasive bladder cancer."9.17Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase ( Buyyounouski, MK; Hunt, D; Kaufman, DS; Mitin, T; Sandler, H; Shipley, WU; Uzzo, R; Wu, CL; Zietman, AL, 2013)
"Combination three-drug chemotherapy with adriamycin (ADM), cyclophosphamide (CPM), and 5-fluorouracil (5-FU) was performed in 24 cases of advanced bladder cancer who underwent surgical treatment, and three cases with recurrent or metastatic bladder cancer."7.66Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil. ( Machida, T; Masuda, F; Ohishi, Y; Tashiro, K, 1983)
"The cytotoxic drug combination of adriamycin and 5-fluorouracil has resulted in a 35% objective response in 20 patients with advanced bladder cancer."7.65Treatment of advanced bladder cancer with adriamycin and 5-fluorouracil. ( Cross, RJ; Glashan, RW; Humphrey, CS; Robinson, RG; Smith, PH; Williams, RE, 1976)
"Eligible patients had muscle invasive bladder cancer (clinical stages T2-T4) with nodal involvement at or below the level of bifurcation of the iliac vessels, were medically or surgically inoperable, or refused cystectomy."6.70Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. ( Al-Sarraf, M; Balcerzak, SP; Crawford, ED; Forman, J; Glass, TR; Grossman, HB; Hussain, MH; Jones, J; Sakr, W; Smith, DC, 2001)
"The nonrecurrence rate and side effects were both compared among the 4 groups."6.68Significance of the preoperative intravesical instillation of doxorubicin and the oral administration of 5-fluorouracil in preventing recurrence after a transurethral resection of superficial bladder cancer. Kyushu University Urological Oncology Group. ( Ariyoshi, A; Iguchi, A; Kumazawa, J; Kuriya, N; Naito, S; Omoto, T; Osada, Y; Sagiyama, K, 1997)
"5-Fluorouracil was administered p."6.66Early intravesical instillation of adriamycin with oral administration of 5-fluorouracil after transurethral resection for superficial bladder cancer: preliminary results. ( Ariyoshi, A; Iguchi, A; Kumazawa, J; Omoto, T; Osada, Y; Sagiyama, K; Ueda, T, 1987)
"Twenty-three muscle-invasive bladder cancer patients who were unfit for or unwilling to receive radical cystectomy were enrolled in this study."5.32Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer. ( Chang, PL; Chen, CS; Chen, MF; Chen, WC; Chu, SH; Chuang, CK; Hong, JH; Liaw, CC; Lin, PY; Wu, CT, 2003)
"To treat superficial bladder cancer or invasive bladder cancer presenting as a solitary tumor, conservative therapy such as transurethral resection of bladder tumor or partial cystectomy has long been carried out."5.28[Study of preventive effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU) or combination of HCFU and 2.5-di-O-acetyl-D-glucaro (1-4) (6-3) dilactone (SLA) after preservative operation against bladder cancer]. ( Hayahara, N; Horii, A; Kashihara, N; Kawakita, J; Kishimoto, T; Maekawa, M; Morikawa, Y; Nishijima, T; Wada, S; Yasumoto, R, 1992)
"We assessed effectiveness, safety, and tolerability of paclitaxel or fluorouracil when added to radiation plus cisplatin followed by adjuvant chemotherapy in a programme of selected bladder preservation for patients with muscle invasive bladder cancer."5.17Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase ( Buyyounouski, MK; Hunt, D; Kaufman, DS; Mitin, T; Sandler, H; Shipley, WU; Uzzo, R; Wu, CL; Zietman, AL, 2013)
"The long-term update of US GI Intergroup RTOG 98-11 anal cancer trial found that concurrent chemoradiation (CCRT) with fluorouracil (5-FU) plus mitomycin had a significant impact on disease-free survival (DFS) and overall survival (OS) compared with induction plus concurrent 5-FU plus cisplatin."5.17Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. ( Ajani, JA; Benson, AB; Gunderson, LL; Haddock, MG; Mayer, RJ; Moughan, J; Pedersen, JE; Rich, TA; Thomas, CR; Willett, CG; Winter, KA, 2013)
"A multi-institutional phase 2 trial assessed the utility of dose-painted intensity modulated radiation therapy (DP-IMRT) in reducing grade 2+ combined acute gastrointestinal and genitourinary adverse events (AEs) of 5-fluorouracil (5FU) and mitomycin-C (MMC) chemoradiation for anal cancer by at least 15% compared with the conventional radiation/5FU/MMC arm from RTOG 9811."5.17RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. ( Esthappan, J; Goodyear, MD; Haddock, MG; Kachnic, LA; Myerson, RJ; Parikh, PJ; Rotman, M; Safran, H; Willett, CG; Willins, J; Winter, K, 2013)
"We conducted a phase I/II study investigating synchronous chemoradiotherapy with mitomycin C and infusional 5-fluorouracil (5-FU) in muscle invasive bladder cancer."5.11Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer. ( Glaholm, JG; Hussain, SA; James, ND; Peake, DR; Stocken, DD; Wallace, DM; Zarkar, A, 2004)
"Between 1976 and 2008, 116 patients with T2 node-negative anal cancer were treated curatively with RT alone (n=48) or by combined chemoradiation therapy (CRT) (n=68) incorporating mitomycin C and 5-fluorouracil."3.79Elective inguinal node irradiation in early-stage T2N0 anal cancer: prognostic impact on locoregional control. ( Allal, AS; Betz, M; Bieri, S; Ris, F; Roche, B; Roth, AD; Zilli, T, 2013)
"5-fluorouracil (5-FU) is an anticancer agent widely used against various tumors including bladder cancer."3.72[Orotate phosphoribosyl transferase in bladder cancer]. ( Furuse, H; Harada, M; Hirano, Y; Mugiya, S; Ozono, S; Suzuki, K; Ushiyama, T, 2004)
" We conducted a study using FOLFOX-4 (oxaliplatin, fluorouracil, folinic acid) in pre-treated advanced bladder cancer patients."3.72FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. ( Autorino, R; Bianco, AR; D'Armiento, M; De Placido, S; Di Lorenzo, G; Giordano, A; Giuliano, M, 2004)
" The present study also suggested that we might be able to exclude cases of bladder cancer in which 5-fluorouracil group medicines would be inappropriate candidates in treatment options by measuring both TP and DPD levels in the tumor."3.71Thymidine phosphorylase and dihydropyrimidine dehydrogenase in bladder cancer. ( Hariu, K; Iizumi, T; Sato, M; Sato, S; Shimizu, H; Tomomasa, H; Umeda, T, 2002)
" DPD is also the principal enzyme involved in the degradation of 5-fluorouracil (5-FU), which is one of the anticancer chemotherapeutic agents currently used in the treatment of bladder cancer."3.71The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer. ( Fukushima, M; Kawauchi, A; Miki, T; Mizutani, Y; Ukimura, O; Wada, H; Yoshida, O, 2001)
"Treatment of the T24 human bladder cancer cell line with anti-Fas mAb in combination with 5-fluorouracil, mitomycin C or methotrexate did not overcome resistance to these agents."3.70Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II). ( Bonavida, B; Mizutani, Y; Yoshida, O, 1998)
"Concurrent 2-drug chemoradiotherapy with cisplatin and 5-fluorouracil is feasible without major toxicity and offers a potentially curative and conservative treatment for patients with localized muscle-invasive bladder cancer."3.70[Treatment of infiltrating cancer of the bladder with cisplatin, fluorouracil, and concurrent radiotherapy: results of a pilot study]. ( Berger, C; Chauvet, B; Davin, JL; Félix-Faure, C; Reboul, F; Vincent, P, 1998)
"Forty-two consecutive patients with anal canal cancer were treated with 15 fractions of 30-Gy photon beam radiation therapy administered anteroposterior-posteroanterior in conjunction with chemotherapy with 5-fluorouracil and mitomycin C."3.69Cancer of the anal canal: treatment with chemotherapy and low-dose radiation therapy. ( Anderson, PJ; Frost, DB; Kagan, AR; Latino, F; Peddada, AV; Rao, AR; Shah, KH; Smith, DE, 1994)
"To improve the results obtained by cystectomy alone and to determine the possibilities of conservative treatment in invasive bladder cancer, we designed a prospective study using a combination of fluorouracil (5-FU) plus cisplatin and concomitant radiation therapy, followed by either cystectomy or additional chemoradiotherapy."3.68Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. ( Baillet, F; Brunel, P; Chretien, Y; Colardelle, F; Delanian, S; Dufour, B; Housset, M; Huart, J; Maulard, C, 1993)
"Nineteen patients with locally advanced bladder cancer were treated with irradiation and concomitant 5-fluorouracil intravenous infusion with or without bolus mitomycin."3.67Treatment of advanced bladder carcinoma with irradiation and concomitant 5-fluorouracil infusion. ( Aziz, H; Braverman, A; Choi, K; Laungani, GB; Macchia, R; Rosenthal, J; Rotman, M; Silverstein, M, 1987)
"Two VPM-CisCF chemotherapy regimens (vincristine (VCR), peplomycin (PEP), methotrexate (MTX), cis-diamminedichloroplatinum (II) (CDDP), cytosine arabinoside (Ara-C) and 5-fluorouracil (5-FU), established using human bladder cancer xenografts in nude mice were applied for advanced urothelial cancer."3.67[Sequential combination chemotherapy consisting of vincristine, peplomycin, methotrexate, cis-diamminedichloroplatinum (II), cytosine arabinoside and 5-fluorouracil, for advanced urothelial cancer]. ( Hida, S; Okada, K; Ooishi, K; Yamauchi, T; Yoshida, O, 1985)
"Neoadjuvant therapy combining 5-fluorouracil, mitomycin C, and moderate-dose radiotherapy was given preoperatively to 29 patients with adenocarcinoma of the rectum, 3 patients with squamous cell cancer, and 1 patient with basaloid carcinoma of the anus."3.67Combined preoperative neoadjuvant radiotherapy and chemotherapy for anal and rectal cancer. ( Muff, NS; Shetabi, H; Smith, DE, 1986)
"Six patients with metastatic urothelial carcinoma--4 transitional cell carcinomas and 2 adenocarcinomas--were treated with cis-platinum (CDDP), adriamycin (ADM) and 5-fluorouracil (5-FU)."3.66[Chemotherapy of metastatic urothelial carcinoma]. ( Kawai, T; Kihara, K; Ogawa, M; Sakuramoto, T; Washizuka, M, 1982)
"Combination three-drug chemotherapy with adriamycin (ADM), cyclophosphamide (CPM), and 5-fluorouracil (5-FU) was performed in 24 cases of advanced bladder cancer who underwent surgical treatment, and three cases with recurrent or metastatic bladder cancer."3.66Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil. ( Machida, T; Masuda, F; Ohishi, Y; Tashiro, K, 1983)
"Arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation achieves a definite objective improvement in patients with estrogen-resistant adenocarcinoma of the prostate."3.65Use of arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation as a treatment for carcinoma of the prostate and bladder. ( Hoffman, AA; Nevin, JE, 1975)
"The cytotoxic drug combination of adriamycin and 5-fluorouracil has resulted in a 35% objective response in 20 patients with advanced bladder cancer."3.65Treatment of advanced bladder cancer with adriamycin and 5-fluorouracil. ( Cross, RJ; Glashan, RW; Humphrey, CS; Robinson, RG; Smith, PH; Williams, RE, 1976)
"18 patients with category T3 bladder cancer were treated with a combination of radical radiotherapy followed after an interval of 1-3 months by pulsed chemotherapy with adriamycin and 5-fluorouracil."3.65A toxicity study of the treatment of T3 bladder tumours with a combination of radiotherapy and chemotherapy. ( Glashan, RW; Houghton, AL; Robinson, MR, 1977)
"Eligible patients had muscle invasive bladder cancer (clinical stages T2-T4) with nodal involvement at or below the level of bifurcation of the iliac vessels, were medically or surgically inoperable, or refused cystectomy."2.70Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. ( Al-Sarraf, M; Balcerzak, SP; Crawford, ED; Forman, J; Glass, TR; Grossman, HB; Hussain, MH; Jones, J; Sakr, W; Smith, DC, 2001)
"The management of locally advanced bladder cancer remains controversial with poor local control with radiotherapy alone."2.70A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer. ( Glaholm, JG; Hussain, SA; James, ND; Moffitt, DD; Peake, D; Wallace, DM, 2001)
" Dosage in subsequent cycles was adjusted according to toxicity."2.69A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma. ( Kantoff, PW; Loughlin, KR; Manola, J; Oh, WK; Richie, JP, 1999)
"Gallium nitrate and 5-FU were each administered by continuous 5-day infusions every 28 days."2.68Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma. ( Bajorin, DF; Heineman, M; Hilton, S; Hirsch, J; Kelly, WK; Mazumdar, M; McCaffrey, JA; Sadan, S; Scher, HI, 1997)
"The nonrecurrence rate and side effects were both compared among the 4 groups."2.68Significance of the preoperative intravesical instillation of doxorubicin and the oral administration of 5-fluorouracil in preventing recurrence after a transurethral resection of superficial bladder cancer. Kyushu University Urological Oncology Group. ( Ariyoshi, A; Iguchi, A; Kumazawa, J; Kuriya, N; Naito, S; Omoto, T; Osada, Y; Sagiyama, K, 1997)
"or t."2.66[Phase II study of 5-FU tablet in bladder tumor]. ( Fukuoka, H; Fukushima, S; Furuhata, A; Ishizuka, E; Kondo, I; Kubota, Y; Moriyama, M; Nagamoto, A; Satomi, Y; Shuin, T, 1989)
"5-Fluorouracil was administered p."2.66Early intravesical instillation of adriamycin with oral administration of 5-fluorouracil after transurethral resection for superficial bladder cancer: preliminary results. ( Ariyoshi, A; Iguchi, A; Kumazawa, J; Omoto, T; Osada, Y; Sagiyama, K; Ueda, T, 1987)
"The Southeastern Cancer Study Group has evaluated 5-fluorouracil administered intravenously weekly at a dosage of 600 mg."2.65A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. ( Bartolucci, AA; Hemstreet, G; Hester, M; Smalley, RV, 1981)
"Use of the conservative approach in bladder cancer now appears to be a tangible reality for selected patients, but these combined modalities have not yet been tested in randomized trials."2.40[Concurrent radio-chemotherapy in infiltrating cancer of the bladder: a new therapeutic approach?]. ( Baillet, F; Chrétien, Y; Dufour, B; Durdux, C; Housset, M; Méjean, A, 1998)
"We present an additional case of rectal squamous cell carcinoma (SCC) complicating chronic ulcerative colitis in a 33-year-old woman who had the disease for 15 years."2.39Squamous cell carcinoma complicating idiopathic inflammatory bowel disease. ( Butler, B; Doerr, R; Kulaylat, MN; Satchidanand, SK; Singh, A, 1995)
"Patients with muscle-invasive bladder cancer (MIBC) often undergo various preoperative treatments to improve survival; however, their efficacy and safety remain unclear."1.42Efficacy and safety of systemic chemotherapy and intra-arterial chemotherapy with/without radiotherapy for bladder preservation or as neo-adjuvant therapy in patients with muscle-invasive bladder cancer: a single-centre study of 163 patients. ( Hayashi, N; Matsuo, T; Miyata, Y; Nomata, K; Ohba, K; Sakai, H; Sakamoto, I; Uetani, M, 2015)
"Superficial bladder cancer is often multifocal, has high recurrences after surgical resection and recurs after intravesical live Bacillus Calmette-Guérin."1.38Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer. ( Annels, NE; Coffin, RS; Harrington, KJ; Horvath, A; Melcher, AA; Metcalf, S; Mostafid, H; Pandha, HS; Pencavel, T; Peschard, P; Price, T; Seth, R; Simpson, GR, 2012)
"At pretreatment assessment, anal cancer was identified by PET-CT in 47 patients (88."1.38Role of positron emission tomography-computed tomography in the management of anal cancer. ( Baccega, M; Bellò, M; Cassoni, P; Cravero, F; Filippini, C; Fora, G; Lesca, A; Milanesi, E; Mistrangelo, M; Morino, M; Munoz, FH; Pelosi, E; Racca, P; Ricardi, U; Skanjeti, A, 2012)
"Capecitabine was administered at a median dose of 1600 mg/m2/day (range, 1200-1800 mg/m2)."1.33A single institution experience with concurrent capecitabine and radiation therapy in weak and/or elderly patients with urothelial cancer. ( Fontana, J; Forman, J; Frazier, A; Patel, B; Pontes, E; Vaishampayan, U, 2005)
"Twenty-three muscle-invasive bladder cancer patients who were unfit for or unwilling to receive radical cystectomy were enrolled in this study."1.32Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer. ( Chang, PL; Chen, CS; Chen, MF; Chen, WC; Chu, SH; Chuang, CK; Hong, JH; Liaw, CC; Lin, PY; Wu, CT, 2003)
"Of 149 consecutive patients treated for cancer of the bladder, 14 patients met eligibility criteria."1.32Tolerance of radiotherapy and chemotherapy in elderly patients with bladder cancer. ( Goffin, JR; Rajan, R; Souhami, L, 2004)
"Superficial bladder cancer patients who had undergone transurethral resection were divided into two groups, a recurrent and a nonrecurrent group."1.32Clinical significance of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in transitional cell cancer. ( Fujita, K; Hirano, Y; Kageyama, S; Suzuki, K; Ushiyama, T, 2003)
" This is the first report of non-invasive monitoring of toxic 5-FU metabolites in normal human tissues."1.31Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatment. ( Griffiths, JR; Howe, FA; Lofts, F; McIntyre, DJ; McSheehy, PM; Nicholson, G; Noordhuis, P; Peters, GJ; Price, NM; Rodrigues, LM; Smid, K; Stubbs, M; Wadsworth, P, 2001)
"Animals bearing established B16 melanoma or MB-49 bladder carcinoma were used to study the most effective scheduling of recombinant murine IL-12 (rmIL-12), along with systemic chemotherapy."1.30Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma. ( Ara, G; Buxton, D; Leonard, J; Schaub, RG; Teicher, BA, 1997)
"Then, 23 cases with local relapsed prostate cancer and two cases with endocrine-resistant prostate cancer received chemotherapy."1.30[Intraarterial chemotherapy via reservoir system for far-advanced bladder and prostate cancer]. ( Deguchi, T; Kawada, Y; Kuriyama, M; Nakano, M; Shinoda, I; Takahashi, Y; Takeuchi, T; Yamamoto, N; Yasuda, M; Yoh, M, 1998)
"Treatment of bladder cancer by TURB and RT/RCT is an alternative to primary cystectomy."1.30Radiotherapy alone or radiochemotherapy with platin derivatives following transurethral resection of the bladder. Organ preservation and survival after treatment of bladder cancer. ( Birkenhake, S; Kühn, R; Martus, P; Sauer, R; Schrott, KM, 1998)
"A human bladder cancer cell line resistant to adriamycin (ADM), T24/ADM9 has been established in vitro by exposing T24 parent cells to progressively higher concentrations of the drug over a period of 12 months."1.29Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line. ( Hasegawa, S; Koga, H; Kotoh, S; Kumazawa, J; Kuwano, M; Naito, S; Yokomizo, A, 1995)
"To treat superficial bladder cancer or invasive bladder cancer presenting as a solitary tumor, conservative therapy such as transurethral resection of bladder tumor or partial cystectomy has long been carried out."1.28[Study of preventive effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU) or combination of HCFU and 2.5-di-O-acetyl-D-glucaro (1-4) (6-3) dilactone (SLA) after preservative operation against bladder cancer]. ( Hayahara, N; Horii, A; Kashihara, N; Kawakita, J; Kishimoto, T; Maekawa, M; Morikawa, Y; Nishijima, T; Wada, S; Yasumoto, R, 1992)
"58-year-old male with bladder cancer complicated acute myocardial infarction (aMI) were treated by 5-FU 300 mg/day orally for approximately one and a half months as single drug chemotherapy preoperatively."1.28[Single drug chemotherapy with 5-FU oral administration of bladder cancer]. ( Hasegawa, K; Ikeuchi, T; Kai, Y; Onodera, Y; Sasaki, H; Ueno, M; Yoshikawa, H, 1990)
"Seventy patients with squamous cell carcinoma or cloacogenic carcinoma of the anus treated from 1979-1987 were reviewed."1.28Radiotherapy for anal cancer: experience from 1979-1987. ( Ajani, JA; Delclos, L; Hughes, LL; Martin, RG; Rich, TA, 1989)
" It should be emphasized that these patients had refused any other modality, including surgery, radiation therapy, and standard dosage chemotherapy."1.27The treatment of primary operable transitional cell cancer of the bladder without cystectomy. Preliminary report. ( Cole, DR; Pung, F; Pung, JL; Sanchez, RS, 1983)
" During the first week of radiotherapy, 5-fluorouracil (1000 mg/m2 daily for four days by continuous infusion), and mitomycin (10 mg/m2 on day 1) were administered; four weeks later, a second cycle at the same dosage followed."1.27[Function-preserving treatment of anal cancer using simultaneous radio- and chemotherapy]. ( Dunst, J; Reichard, U; Sauer, R; Wolf, N, 1987)
"A case of untreated bladder cancer with an unusual clinical course in a 48-year-old man is reported."1.27[An autopsy case of untreated bladder cancer]. ( Arai, Y; Ishida, A; Pak, K; Tomoyoshi, T, 1987)
" If toxicity is intolerable, the dosage of CDDP and ADM was decreased in thirty percent."1.27[Therapeutic experiences of cis-diamminedichloroplatinum, adriamycin and 5-fluorouracil combination chemotherapy in advanced urothelial cancer, with special reference to adjuvant chemotherapy in invasive urothelial cancer]. ( Nakagawa, T; Nishimura, K; Ogawa, O; Taniguchi, T; Yoshimura, N, 1986)
"The in vivo chemosensitivity test for bladder cancer, using the human bladder cancer xenografts (BT-8 and BT-11 strains) in nude mice (BALB/c) and the BBN-BT-1 bladder cancer strain in BALB/c hetero-mouse which was induced by peroral long-period administration of N-butyl-N-(4-hydroxybutyl) nitrosamine and transplantable into the subcutaneous of mouse, were examined especially in respect to the difference of chemosensitivity between young and old straining and the prospective propriety for clinical application."1.27[Chemosensitivity test for bladder cancer in a nude-mice experimental system]. ( Kawai, T; Okada, K; Yamauchi, T; Yoshida, O, 1986)
"Eight patients with deeply invasive bladder cancer were treated with cis-DDP alone or in combination with other drugs following radical cystectomy."1.27[Chemotherapy for advanced bladder cancer: clinical evaluation of chemotherapy for locally advanced or metastatic bladder cancer and adjuvant chemotherapy for deeply invasive bladder cancer following radical cystectomy]. ( Hirano, A; Ogawa, T; Ohkawa, T; Shinka, T; Uekado, Y; Watanabe, T; Yamamoto, S; Yoshida, T, 1985)
"Thermotherapy combined with tegafur (FT-207) and Picibanil was performed in 13 patients with cancer of the urinary bladder."1.27[Thermotherapy for cancer of the urinary bladder in combination with tegafur suppository and picibanil--concentrations of tegafur in the serum and tissues in bladder carcinoma]. ( Arai, T; Honda, M; Kanbe, K; Kaneko, K; Maeda, S; Mukae, K; Murahashi, I; Sakuma, H; Tabata, Y; Takasaki, E, 1985)
"Squamous cell carcinoma was found in 4 horses and appears to be the most common bladder tumor in the horse."1.27Neoplasia of the equine urinary bladder as a cause of hematuria. ( Carlson, GP; Fischer, AT; Hackett, RP; Spier, S, 1985)
"Treatment with Semustine (Methyl-CCNU) resulted in a partial response lasting 15 months."1.26Response of metastatic cloacogenic carcinoma to treatment with semustine. ( Wampler, GL; Zimm, S, 1981)
"Thiotepa was found to produce marked acantholysis in 43 per cent of those studied."1.26The effect of chemotherapeutic agents on the ultrastructure of transitional cell carcinoma in tissue culture. ( Adelstein, E; Haigh, J; Khare, N; Oxenhandler, R; Ross, G; Weaver, D, 1980)
"Regional arterial infusion of high doses of anti-cancer drugs combined with direct hemoperfusion was done in 12 patients with malignancies of the urinary tract."1.26Efficacy and side effects of the regional arterial infusion of anti-cancer drugs combined with direct hemoperfusion in malignancies of the urinary tract. ( Harada, T; Nishizawa, O; Ohmura, H; Tsuchida, S, 1982)
"Cure following surgery of bladder cancer is limited by recurrence of the original tumor or by the development of new primary tumors."1.26Effectiveness of long-term chemotherapy and/or BCG on murine bladder cancer. ( Soloway, MS, 1978)

Research

Studies (165)

TimeframeStudies, this research(%)All Research%
pre-199081 (49.09)18.7374
1990's40 (24.24)18.2507
2000's27 (16.36)29.6817
2010's17 (10.30)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Liaw, CC2
Chuang, CK2
Chang, YH1
Liao, TY1
Chang, JW1
Juan, YH1
Tselis, N1
Prott, FJ1
Ott, O1
Weiss, C1
Rödel, C2
Zilli, T1
Betz, M1
Bieri, S1
Ris, F1
Roche, B1
Roth, AD1
Allal, AS1
Mitin, T2
Hunt, D1
Shipley, WU3
Kaufman, DS3
Uzzo, R1
Wu, CL1
Buyyounouski, MK1
Sandler, H1
Zietman, AL3
Huddart, RA2
Hall, E1
Hussain, SA3
Jenkins, P1
Rawlings, C1
Tremlett, J1
Crundwell, M1
Adab, FA1
Sheehan, D1
Syndikus, I1
Hendron, C1
Lewis, R1
Waters, R1
James, ND3
Gunderson, LL1
Moughan, J1
Ajani, JA3
Pedersen, JE1
Winter, KA1
Benson, AB1
Thomas, CR1
Mayer, RJ1
Haddock, MG2
Rich, TA3
Willett, CG2
Miyata, Y1
Nomata, K1
Ohba, K1
Matsuo, T1
Hayashi, N2
Sakamoto, I1
Uetani, M1
Sakai, H1
Gakis, G1
Morgan, TM1
Daneshmand, S1
Keegan, KA1
Todenhöfer, T1
Mischinger, J1
Schubert, T1
Zaid, HB1
Hrbacek, J1
Ali-El-Dein, B1
Clayman, RH1
Galland, S1
Olugbade, K1
Rink, M1
Fritsche, HM1
Burger, M1
Chang, SS1
Babjuk, M1
Thalmann, GN1
Stenzl, A1
Efstathiou, JA1
Li, L1
Zhang, CL1
Kang, L1
Wang, RF1
Yan, P1
Zhao, Q1
Yin, L1
Guo, FQ1
George, A1
Heney, NM2
Uzzo, RG1
Dreicer, R1
Wallace, HJ1
Souhami, L2
Dobelbower, MC1
Sandler, HM1
Poortmans, PM1
Richaud, P1
Collette, L2
Ho Goey, S1
Pierart, M1
Van Der Hulst, M1
Bolla, M1
Highley, MS1
Griffiths, GO1
Uscinska, BM1
Barber, JB1
Parmar, MK1
Harper, PG1
Nishikawa, T1
Kohjimoto, Y1
Nishihata, M1
Ebisuno, S1
Hara, I1
Seo, YR1
Kim, SH1
Kim, HJ1
Kim, CK1
Park, SK1
Koh, ES1
Hong, DS1
Lagrange, JL1
Bascoul-Mollevi, C1
Geoffrois, L1
Beckendorf, V1
Ferrero, JM1
Joly, F1
Allouache, N1
Bachaud, JM1
Chevreau, C1
Kramar, A1
Chauvet, B2
Bhattacharyya, M1
Powles, T1
Mutsvangwa, K1
Wilson, P1
Oliver, T1
Shamash, J1
De Bari, B1
Lestrade, L1
Chekrine, T1
Shakir Shakir, I1
Ardiet, JM1
Chapet, O1
Mornex, F1
Simpson, GR1
Horvath, A1
Annels, NE1
Pencavel, T1
Metcalf, S1
Seth, R1
Peschard, P1
Price, T1
Coffin, RS1
Mostafid, H1
Melcher, AA1
Harrington, KJ1
Pandha, HS1
Mistrangelo, M1
Pelosi, E1
Bellò, M1
Ricardi, U1
Milanesi, E1
Cassoni, P1
Baccega, M1
Filippini, C1
Racca, P1
Lesca, A1
Munoz, FH1
Fora, G1
Skanjeti, A1
Cravero, F1
Morino, M1
Kachnic, LA1
Winter, K1
Myerson, RJ1
Goodyear, MD1
Willins, J1
Esthappan, J1
Rotman, M3
Parikh, PJ1
Safran, H1
Maezawa, T1
Yonese, J2
Tsukamoto, T1
Ishii, N1
Fukui, I2
Hirano, Y2
Kageyama, S1
Ushiyama, T2
Suzuki, K3
Fujita, K1
Chen, WC1
Chen, MF1
Chen, CS1
Lin, PY1
Chang, PL1
Chu, SH1
Wu, CT1
Hong, JH1
Graf, R1
Wust, P1
Hildebrandt, B1
Gögler, H1
Ullrich, R1
Herrmann, R1
Riess, H1
Felix, R1
LYTTON, B1
MARK, JB1
HARVARD, BM1
REITEMEIER, RJ1
MOERTEL, CG1
BLACKBURN, CM1
HARROLD, MW1
EDWARDS, CN1
GRAVEY, FK1
Peyromaure, M1
Slama, J1
Beuzeboc, P1
Ponvert, D1
Debré, B1
Zerbib, M1
Goffin, JR1
Rajan, R1
Touboul, E2
Moureau-Zabotto, L1
Lerouge, D1
Pène, F2
Deniaud-Alexandre, E1
Tiret, E2
Sezeur, A1
Houry, S1
Gallot, D2
Parc, R2
Schlienger, M2
Laugier, A2
Stocken, DD1
Peake, DR1
Glaholm, JG2
Zarkar, A1
Wallace, DM2
George, L1
Bladou, F1
Bardou, VJ1
Gravis, G1
Tallet, A1
Alzieu, C1
Serment, G1
Salem, N1
Furuse, H1
Harada, M1
Mugiya, S1
Ozono, S1
Di Lorenzo, G1
Autorino, R1
Giordano, A1
Giuliano, M1
D'Armiento, M1
Bianco, AR1
De Placido, S1
Patel, B1
Forman, J2
Fontana, J1
Frazier, A1
Pontes, E1
Vaishampayan, U1
Woodruff, CA1
Amrikachi, M1
Hsu, S1
Lin, CC1
Hsu, CH1
Huang, CY1
Cheng, AL1
Vogelzang, NJ1
Pu, YS1
Siefker-Radtke, A1
Sanghera, P1
Ho, K1
Muscroft, T1
Hartley, A1
Higano, CS2
Tangen, CM1
Sakr, WA1
Faulkner, J1
Rivkin, SE1
Meyers, FJ1
Hussain, M1
Baker, LH1
Russell, KJ3
Crawford, ED3
Shrivastav, S1
Paulson, DF1
Harada, T1
Ohmura, H1
Nishizawa, O1
Tsuchida, S1
Salem, PA1
Richards, B1
Bastable, JR1
Freedman, L1
Glashan, RW3
Harris, G1
Newling, DW1
Robinson, MR2
Smith, PH2
Torti, FM1
Harker, WG1
Akiyama, J1
Sagara, Y1
Takeda, Y1
Mishina, T1
Kobayashi, T1
Maegawa, M1
Nakao, M1
Nakagawa, S1
Watanabe, H1
Tiver, KW1
Langlands, AO1
Cummings, B1
Keane, T1
Thomas, G1
Harwood, A1
Rider, W1
Carey, RW1
Kihara, K3
Kusuyama, H2
Washizuka, M3
Kawai, T4
Fujioka, H2
Tada, Y1
Nakano, E1
Matsuda, M1
Osafune, M2
Sagawa, S1
Takaha, M1
Sonoda, T1
Tashiro, K2
Machida, T3
Masuda, F1
Ohishi, Y1
Cole, DR1
Pung, JL1
Sanchez, RS1
Pung, F1
Sulkes, A1
Fuks, Z1
Kotake, T3
Usami, M1
Miki, T2
Kuroda, M1
Obata, K3
Takasugi, Y1
Leissner, KH1
Gustavsson, B1
Weaver, D1
Khare, N1
Haigh, J1
Adelstein, E1
Oxenhandler, R1
Ross, G1
Konnak, JW1
Wallace, S1
Chuang, VP1
Samuels, M1
Johnson, D1
Sakuramoto, T1
Ogawa, M2
Trindade, A1
Samuels, ML1
Logothetis, CJ1
McGeorge, A1
Hart, AJ1
Rundle, JS1
McVie, JG1
Calman, KC1
Veronesi, A5
Magri, MD2
Figoli, F1
Tirelli, U1
Galligioni, E2
Trovò, MG2
Merlo, A3
Dal Bò, V5
Tumolo, S1
Grigoletto, E1
Smalley, RV1
Bartolucci, AA1
Hemstreet, G1
Hester, M1
Zimm, S1
Wampler, GL1
Martino, S1
Samal, B1
Al-Sarraf, M3
Kattan, J1
Culine, S1
Theodore, C2
Droz, JP1
Kulaylat, MN1
Doerr, R1
Butler, B1
Satchidanand, SK1
Singh, A1
Nakagawa, J1
Nakahara, M1
Kitajima, N1
Mizutani, Y3
Fukumoto, M1
Bonavida, B2
Yoshida, O5
Lo Re, G3
Carbone, A3
Talamini, R2
Santarossa, S1
Francini, M4
Monfardini, S3
Ohashi, Y1
Akaza, H2
Isaka, S2
Kagawa, S1
Koiso, K2
Matsumura, Y2
Niijima, T2
Smith, DE2
Shah, KH1
Rao, AR1
Frost, DB1
Latino, F1
Anderson, PJ1
Peddada, AV1
Kagan, AR1
Buffat, L1
Lefkopoulos, D1
Malafosse, M1
Morrison, WH1
Ota, D1
Levin, B1
Housset, M3
Maulard, C1
Chretien, Y3
Dufour, B3
Delanian, S1
Huart, J1
Colardelle, F1
Brunel, P1
Baillet, F2
Kapp, KS1
Kapp, DS1
Stuecklschweiger, G1
Berger, A1
Geyer, E1
Naito, S2
Hasegawa, S1
Yokomizo, A1
Koga, H1
Kotoh, S1
Kuwano, M1
Kumazawa, J3
Mejean, A2
Durdux, C2
Kondás, J1
Engloner, L1
Váczi, L1
Kondér, G1
Fraunholz, IB1
Adamietz, IA1
Lorenz, M1
Staib-Sebler, E1
Böttcher, HD1
McCaffrey, JA1
Hilton, S1
Mazumdar, M1
Sadan, S1
Heineman, M1
Hirsch, J1
Kelly, WK1
Scher, HI1
Bajorin, DF1
Iguchi, A2
Sagiyama, K2
Ariyoshi, A2
Osada, Y2
Omoto, T2
Kuriya, N1
Kish, JA1
Wolf, MK1
Schellhammer, PF1
Hussain, MH2
Einstein, AB1
Otto, T1
Krege, S1
Otto, B1
Goepel, M1
Rübben, H1
Danesi, DT1
Arcangeli, G1
Cruciani, E1
Mecozzi, A1
Saracino, B1
Giacobini, S1
Pannunzio, E1
Biggio, A1
Orefici, F1
Tsujinaka, T1
Murotani, M1
Iihara, K1
Takami, M1
Takada, T1
Kitada, M1
Tsukahara, Y1
Shibata, T1
Niinobu, T1
Inoue, T1
Kimura, M2
Hanada, M1
Nose, T1
Birkenhake, S1
Martus, P1
Kühn, R2
Schrott, KM2
Sauer, R3
Takahashi, Y1
Yamamoto, N1
Deguchi, T1
Kuriyama, M1
Yoh, M1
Yasuda, M1
Nakano, M1
Kawada, Y1
Takeuchi, T1
Shinoda, I1
Félix-Faure, C1
Davin, JL1
Berger, C1
Vincent, P1
Reboul, F1
Schmitt, T1
Armand, C1
Mille, D1
Favrel-Tchakamian, V1
Gilloz, A1
Zehr, EM1
Althausen, AF1
McGovern, FJ1
Kitsukawa, S1
Kinn, T1
Yoshida, T2
Izutami, T1
Ishikawa, Y1
Teicher, BA1
Ara, G1
Buxton, D1
Leonard, J1
Schaub, RG1
Oh, WK1
Manola, J1
Richie, JP1
Loughlin, KR1
Kantoff, PW1
Glass, TR1
Sakr, W1
Smith, DC1
Jones, J1
Balcerzak, SP1
Grossman, HB1
De Mulder, PH1
Sella, A1
Koriakine, O1
Sternberg, CN1
de Balincourt, C1
Wada, H1
Fukushima, M2
Ukimura, O1
Kawauchi, A1
Moffitt, DD1
Peake, D1
Griffiths, JR1
McIntyre, DJ1
Howe, FA1
McSheehy, PM1
Rodrigues, LM1
Wadsworth, P1
Price, NM1
Lofts, F1
Nicholson, G1
Smid, K1
Noordhuis, P1
Peters, GJ1
Stubbs, M1
Iizumi, T1
Hariu, K1
Sato, M1
Sato, S2
Shimizu, H1
Tomomasa, H1
Umeda, T1
Grabenbauer, GG1
Dunst, J2
Papadopoulos, T1
Soloway, MS5
Lundbeck, F1
Christophersen, IS1
Houghton, AL1
Fichardt, T1
Sandison, AG1
Morita, M1
Sato, Y1
Miyakawa, K1
Nevin, JE2
Hoffman, AA1
Collier, D1
Cross, RJ1
Humphrey, CS1
Robinson, RG1
Williams, RE1
Kolosseus, RC1
Fraley, EE1
Blackard, CE1
Melnick, I1
Baggerly, JT1
Landes, R1
Easley, CA1
Sahashi, M1
Ono, Y2
Matsuura, O1
Ohshima, S2
Wada, S1
Yasumoto, R1
Kashihara, N1
Kishimoto, T1
Maekawa, M1
Hayahara, N1
Kawakita, J1
Nishijima, T1
Morikawa, Y1
Horii, A1
Doci, R1
Zucali, R1
Bombelli, L1
Montalto, F1
Lamonica, G1
Nishiyama, T1
Sasagawa, T1
Tanikawa, T1
Katayama, Y1
Kawakami, Y1
Tomita, Y1
Terunuma, M1
Osawa, T1
Kanimoto, Y1
Suzuki, Y1
Miwa, Y1
Akino, H1
Isomatu, Y1
Okada, K4
Bonaventura, A1
Stewart, JF1
Boileau, MA2
Higano, C1
Collins, C2
Russell, AH1
Koh, W1
Cole, SB1
Chapman, WH2
Griffin, TW2
Ueno, M1
Yoshikawa, H1
Hasegawa, K1
Sasaki, H1
Onodera, Y1
Ikeuchi, T1
Kai, Y1
Aziz, H2
Porrazzo, M1
Choi, KN1
Silverstein, M2
Rosenthal, J2
Laungani, G1
Macchia, R2
Yamauchi, T2
Hida, S1
Ooishi, K1
Fujita, T1
Aso, Y1
Al-Kourainy, K1
Crissman, J1
Ensley, J1
Kish, J1
Kelly, J1
Kubota, Y2
Kakizaki, H1
Numasawa, K1
Kato, H1
Hughes, LL1
Delclos, L1
Martin, RG1
Nagamoto, A1
Shuin, T1
Kondo, I1
Moriyama, M1
Satomi, Y1
Fukushima, S1
Fukuoka, H1
Ishizuka, E1
Furuhata, A1
Sischy, B1
Doggett, RL1
Krall, JM1
Taylor, DG1
Sause, WT1
Lipsett, JA1
Seydel, HG2
Morassut, S1
Carmignani, G1
Lelli, G1
Tononi, A1
Bacchetti, P1
Maver, P1
Corrado, G1
Garofalo, F1
De Santis, P1
Pannuti, F1
Muff, NS1
Shetabi, H1
Danil'chenko, SA1
Shlopov, VG1
Serniak, PS1
Geev, IuV1
John, MJ1
Flam, M1
Lovalvo, L1
Mowry, PA1
Reichard, U1
Wolf, N1
Uekado, Y2
Shinka, T2
Hirano, A2
Ohkawa, T2
Sato, K1
Hatano, T1
Miyazato, T1
Saito, S1
Kashiwabara, N1
Igarashi, M1
Koyama, Y1
Hayakawa, M1
Osawa, A1
Amiel, J1
Quintens, H1
Thyss, A1
Caldani, C1
Schneider, M1
Toubol, J1
Maru, A1
Nakagami, Y1
Peppe, H1
Bianchi, C1
Bianchi, O1
Stringa, S1
Ireton, RC1
Koh, WJ1
Griffin, BR1
Pak, K1
Ishida, A1
Arai, Y1
Tomoyoshi, T1
Sorio, R1
Saracchini, S1
Takahashi, T1
Sakata, Y1
Tai, K1
Nagayama, T1
Ishii, Y1
Ueda, T1
Kondo, N1
Ikemoto, I1
Ogawa, O1
Yoshimura, N1
Taniguchi, T1
Nishimura, K1
Nakagawa, T1
Choi, K1
Braverman, A1
Laungani, GB1
Hrushesky, WJ1
Roemeling, RV1
Wood, PA1
Langevin, TR1
Lange, P1
Farley, E1
Ogawa, T1
Yamamoto, S1
Watanabe, T1
Leichman, L1
Nigro, N1
Vaitkevicius, VK1
Considine, B1
Buroker, T1
Bradley, G1
Olchowski, S1
Cummings, G1
Leichman, C1
Murahashi, I1
Mukae, K1
Tabata, Y1
Sakuma, H1
Kanbe, K1
Arai, T1
Kaneko, K1
Honda, M1
Maeda, S1
Takasaki, E1
Fischer, AT1
Spier, S1
Carlson, GP1
Hackett, RP1
Nakada, T1
Akiya, T1
Yoshikawa, M1
Umeda, K1
Katayama, T1
Tomiyama, T1
Greene, LF1
Mulcahy, JJ1
Warren, MM1
Dockerty, MB1
deKernion, JB1
Rose, D1
Persky, L1
Witek, JT1
Spencer, RP1
Harrison, LH1
Cox, CE1
Banks, KW1
Boyce, WH1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II Randomized Trial for Patients With Muscle-Invading Bladder Cancer Evaluating Transurethral Surgery and BID Irradiation Plus Either Paclitaxel and Cisplatin or 5-Fluorouracil and Cisplatin Followed by Selective Bladder Preservation and Gemcitabi[NCT00055601]Phase 297 participants (Actual)Interventional2002-12-31Completed
A Phase 3, Multicenter, Double-Blind Randomized Study of Mitomycin, 5-Fluorouracil and IMRT Combined With or Without Anti-PD-1 in Patients With Locally Advanced Anal Canal Squamous Carcinoma[NCT05374252]Phase 3102 participants (Anticipated)Interventional2022-05-07Recruiting
A Phase II Feasibility Study of Combined Accelerated External Radiation and Chemotherapy With 5FU and CDDP Following Transurethral Resection in Patients With Muscle Invasive Transitional Carcinoma of the Bladder - T2-T3, N0, M0 (UICC 1992)[NCT00003642]Phase 243 participants (Anticipated)Interventional1998-10-31Terminated (stopped due to low accrual)
A Phase II Study of Continuous 5-Fluorouracil (5-FU) in Recurrent Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urinary Tract[NCT00003175]Phase 245 participants (Anticipated)Interventional1997-12-31Completed
A Randomized Phase II Trial Evaluating an Organ-conserving Strategy With Radiotherapy + CDDP + Gemcitabine vs Radiotherapy + CDDP in Muscle-infiltrative Bladder Cancer[NCT01495676]69 participants (Actual)Interventional2011-07-06Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Bladder-intact Survival Rate (5 Years)

Bladder-intact survival was measured from the date of randomization to occurrence of cystectomy or death. Five-year rates were estimated using the Kaplan-Meier method. (NCT00055601)
Timeframe: From the date of randomization to five years.

Interventionpercentage of participants (Number)
Pelvic RT + Paclitaxel + Cisplatin67
Pelvic RT + Fluorouracil + Cisplatin71

Complete Response After Induction

Complete response requires the absence of any tumor in the tumor-site biopsy specimen or elsewhere and a bimanual exam that does not indicate the presence of a tumor mass. (NCT00055601)
Timeframe: From randomization to eight weeks

Interventionpercentage of participants (Number)
Pelvic RT + Paclitaxel + Cisplatin72
Pelvic RT + Fluorouracil + Cisplatin62

Treatment Completion Rate

Radiation therapy and chemotherapy per protocol or within acceptable variation guidelines based on central review. The study was designed for a two-sided binomial test with 87% power and a significance level of 0.05 with a null hypothesis of a 70% completion rate against the alternative 90% completion rate. For each arm, more than 34 out of 43 evaluable patients completing the treatment, would indicate to reject the null hypothesis for a better treatment completion rate. Fewer than 24 out 43 evaluable patients completing the treatment would indicate to reject the null hypothesis for a worse treatment completion rate. Otherwise, the conclusion would be that there is not enough evidence to reject the null hypothesis of a 70% completion rate in either direction. (NCT00055601)
Timeframe: From randomization to 11 weeks

Interventionpercentage of participants (Number)
Pelvic RT + Paclitaxel + Cisplatin67
Pelvic RT + Fluorouracil + Cisplatin53

Reviews

14 reviews available for fluorouracil and Carcinoma, Transitional Cell

ArticleYear
[Radiochemotherapy for invasive bladder cancer : An update].
    Der Urologe. Ausg. A, 2018, Volume: 57, Issue:6

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Biopsy; Carcinoma, Transitional Cell; Chemoradio

2018
[Should the treatment of anal carcinoma be adapted in the elderly? A retrospective analysis of acute toxicities in a French centre and a review of the literature].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2012, Volume: 16, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachythera

2012
Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution.
    Urology, 2004, Volume: 63, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carbopl

2004
Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    Urology, 2004, Volume: 64, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino

2004
Urachal carcinoma: surgical and chemotherapeutic options.
    Expert review of anticancer therapy, 2006, Volume: 6, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cispla

2006
Systemic therapy of bladder cancer.
    Progress in clinical and biological research, 1984, Volume: 162B

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Transit

1984
Chemotherapy of advanced transitional cell carcinoma of the uroepithelium.
    Cancer chemotherapy and pharmacology, 1983, Volume: 11 Suppl

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell;

1983
Synchronous chemotherapy and radiotherapy for carcinoma of the anal canal--an alternative to abdominoperineal resection.
    The Australian and New Zealand journal of surgery, 1984, Volume: 54, Issue:2

    Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous C

1984
Squamous cell carcinoma complicating idiopathic inflammatory bowel disease.
    Journal of surgical oncology, 1995, Volume: 59, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transiti

1995
Interstitial hyperthermia and high dose rate brachytherapy in the treatment of anal cancer: a phase I/II study.
    International journal of radiation oncology, biology, physics, 1994, Jan-01, Volume: 28, Issue:1

    Topics: Adult; Aged; Anus Neoplasms; Brachytherapy; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell;

1994
[Concurrent radio-chemotherapy in infiltrating cancer of the bladder: a new therapeutic approach?].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 1998, Volume: 2 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin

1998
[Successful multidisciplinary treatment for bladder cancer with priapism. A case report].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1998, Volume: 89, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Comb

1998
Invasive bladder cancer: organ preservation by radiochemotherapy.
    Frontiers of radiation therapy and oncology, 2002, Volume: 36

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carbopla

2002
Intravesical and systemic chemotherapy of murine bladder cancer.
    Cancer research, 1977, Volume: 37, Issue:8 Pt 2

    Topics: Animals; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphami

1977

Trials

33 trials available for fluorouracil and Carcinoma, Transitional Cell

ArticleYear
Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase
    The Lancet. Oncology, 2013, Volume: 14, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio

2013
Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004).
    International journal of radiation oncology, biology, physics, 2013, Oct-01, Volume: 87, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2013
Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial.
    International journal of radiation oncology, biology, physics, 2013, Nov-15, Volume: 87, Issue:4

    Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squ

2013
Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.
    International journal of radiation oncology, biology, physics, 2016, Jan-01, Volume: 94, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio

2016
Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder.
    Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Ad

2008
A phase II trial of continuous 5-fluorouracil in recurrent or metastatic transitional cell carcinoma of the urinary tract.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2009, Volume: 21, Issue:5

    Topics: Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Female; Fluorouracil; Humans; Infusion Pu

2009
Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015).
    International journal of radiation oncology, biology, physics, 2011, Jan-01, Volume: 79, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin

2011
A phase II study of mitomycin, fluorouracil, folinic acid, and irinotecan (MFI) for the treatment of transitional cell carcinoma of the bladder.
    Urologic oncology, 2013, Volume: 31, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Transitional

2013
RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
    International journal of radiation oncology, biology, physics, 2013, May-01, Volume: 86, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Analysis of Variance; Antineoplastic Combined Chemothera

2013
Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy.
    Oncology, 2003, Volume: 65, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc

2003
Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer.
    British journal of cancer, 2004, Jun-01, Volume: 90, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Combined Modalit

2004
Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
    The Journal of urology, 2007, Volume: 177, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2007
Adjuvant chemotherapy with doxorubicin (Adriamycin) and 5-fluorouracil in T3, NX, MO bladder cancer treated with radiotherapy.
    British journal of urology, 1983, Volume: 55, Issue:4

    Topics: Carcinoma, Transitional Cell; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Fema

1983
The treatment of advanced carcinoma of the bladder with combination chemotherapy.
    British journal of urology, 1982, Volume: 54, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Clinical Trials as Topic; Cyclophosphamide; Dox

1982
A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma.
    The Journal of urology, 1981, Volume: 125, Issue:2

    Topics: Adenocarcinoma; Carcinoma, Transitional Cell; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug T

1981
Phase II trial of ifosfamide, fluorouracil, and folinic acid (FIFO regimen) in relapsed and refractory urothelial cancer.
    Cancer investigation, 1995, Volume: 13, Issue:3

    Topics: Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms

1995
Prophylactic chemotherapy with intravesical instillation of adriamycin and oral administration of 5-fluorouracil after surgery for superficial bladder cancer. The Japanese Urological Cancer Research Group for Adriamycin.
    Cancer chemotherapy and pharmacology, 1994, Volume: 35 Suppl

    Topics: Administration, Intravesical; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherap

1994
Interstitial hyperthermia and high dose rate brachytherapy in the treatment of anal cancer: a phase I/II study.
    International journal of radiation oncology, biology, physics, 1994, Jan-01, Volume: 28, Issue:1

    Topics: Adult; Aged; Anus Neoplasms; Brachytherapy; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell;

1994
Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio

1997
Significance of the preoperative intravesical instillation of doxorubicin and the oral administration of 5-fluorouracil in preventing recurrence after a transurethral resection of superficial bladder cancer. Kyushu University Urological Oncology Group.
    International journal of urology : official journal of the Japanese Urological Association, 1997, Volume: 4, Issue:4

    Topics: Administration, Intravesical; Administration, Oral; Adult; Aged; Aged, 80 and over; Antibiotics, Ant

1997
Continuous-infusion 5-fluorouracil and cisplatin for advanced/recurrent transitional cell cancer of the bladder: a Southwest Oncology Group trial.
    American journal of clinical oncology, 1997, Volume: 20, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast

1997
[Therapy with mitomycin C, folic acid and 5-fluorouracil in treatment of metastatic, refractory urinary bladder carcinoma--phase II study].
    Der Urologe. Ausg. A, 1997, Volume: 36, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Resistance,

1997
Combined treatment of invasive bladder carcinoma with transurethral resection, induction chemotherapy, and radical radiotherapy plus concomitant protracted infusion of cisplatin and 5-fluorouracil: a phase I study.
    Cancer, 1997, Oct-15, Volume: 80, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Dose-

1997
A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer.
    The Journal of urology, 1998, Volume: 160, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin

1998
A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma.
    Cancer, 1999, Oct-01, Volume: 86, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin

1999
Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study.
    The Journal of urology, 2001, Volume: 165, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitio

2001
Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-alpha as second-line treatment of advanced transitional cell cancer of the urothelial tract.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combi

2000
A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:7

    Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe

2001
Combination chemotherapy for advanced urothelial-tract carcinoma.
    Cancer chemotherapy and pharmacology, 1992, Volume: 30 Suppl

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin

1992
Three-drug combination chemotherapy for advanced urothelial tract carcinoma.
    Cancer chemotherapy and pharmacology, 1987, Volume: 20 Suppl

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Transitional Cell

1987
[Phase II study of 5-FU tablet in bladder tumor].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:4 Pt 1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Carcinoma, Transitional Cell; Drug E

1989
Phase III trial of the Japanese Urological Cancer Research Group for Adriamycin: cyclophosphamide, adriamycin and cisplatinum versus cyclophosphamide, adriamycin and 5-fluorouracil in patients with advanced transitional cell carcinoma of the urinary bladd
    Cancer chemotherapy and pharmacology, 1987, Volume: 20 Suppl

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin

1987
Early intravesical instillation of adriamycin with oral administration of 5-fluorouracil after transurethral resection for superficial bladder cancer: preliminary results.
    Cancer chemotherapy and pharmacology, 1987, Volume: 20 Suppl

    Topics: Administration, Intravesical; Administration, Oral; Aged; Carcinoma, Transitional Cell; Combined Mod

1987

Other Studies

119 other studies available for fluorouracil and Carcinoma, Transitional Cell

ArticleYear
Bladder Urothelial Carcinoma with Peritoneal Involvement: Benefit of Continuous Maintenance Chemotherapy.
    Anticancer research, 2017, Volume: 37, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio

2017
Elective inguinal node irradiation in early-stage T2N0 anal cancer: prognostic impact on locoregional control.
    International journal of radiation oncology, biology, physics, 2013, Sep-01, Volume: 87, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc

2013
Efficacy and safety of systemic chemotherapy and intra-arterial chemotherapy with/without radiotherapy for bladder preservation or as neo-adjuvant therapy in patients with muscle-invasive bladder cancer: a single-centre study of 163 patients.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2015, Volume: 41, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Tra

2015
Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:8

    Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Carb

2015
Enhanced EJ Cell Killing of (125)I Radiation by Combining with Cytosine Deaminase Gene Therapy Regulated by Synthetic Radio-Responsive Promoter.
    Cancer biotherapy & radiopharmaceuticals, 2015, Volume: 30, Issue:8

    Topics: Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Survival; Cyto

2015
Synergistic antitumor effects of fleroxacin with 5-fluorouracil in vitro and in vivo for bladder cancer cell lines.
    Urology, 2009, Volume: 74, Issue:6

    Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Cell Line, Tumor; Cells, Cul

2009
Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report.
    Journal of hematology & oncology, 2010, Jan-20, Volume: 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Disease Progression; F

2010
Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer.
    British journal of cancer, 2012, Jan-31, Volume: 106, Issue:3

    Topics: Administration, Intravesical; Animals; Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; Cr

2012
Role of positron emission tomography-computed tomography in the management of anal cancer.
    International journal of radiation oncology, biology, physics, 2012, Sep-01, Volume: 84, Issue:1

    Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma,

2012
[Combination chemotherapy with ifosfamide, 5-fuluorouracil, etoposide and cisplatin for advanced urothelial cancer: the treatment results and significance of tumor marker evaluation in response assessment of chemotherapy].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2002, Volume: 93, Issue:7

    Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9

2002
Clinical significance of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in transitional cell cancer.
    Cancer chemotherapy and pharmacology, 2003, Volume: 51, Issue:1

    Topics: Carcinoma, Transitional Cell; Dihydrouracil Dehydrogenase (NADP); Fluorouracil; Humans; Oxidoreducta

2003
Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer.
    International journal of radiation oncology, biology, physics, 2003, Jul-01, Volume: 56, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cel

2003
Continuous intraarterial chemotherapy in advanced bladder cancer. A preliminary report.
    Connecticut medicine, 1963, Volume: 27

    Topics: Carcinoma; Carcinoma, Papillary; Carcinoma, Transitional Cell; Fluorouracil; Humans; Neoplasms; Urin

1963
VINCRISTINE (NSC-67574) THERAPY OF ADULT PATIENTS WITH SOLID TUMORS.
    Cancer chemotherapy reports, 1964, Volume: 34

    Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Bronchogenic; Carcinoma, Squamous

1964
TREATMENT OF BLADDER TUMORS BY DIRECT INSTILLATION OF 5-FLUOROURACIL. EXPERIMENTAL OBSERVATIONS IN DOGS.
    Investigative urology, 1964, Volume: 2

    Topics: Amines; Animals; Carcinogens; Carcinoma; Carcinoma, Transitional Cell; Dogs; Fluorouracil; Gastroent

1964
Tolerance of radiotherapy and chemotherapy in elderly patients with bladder cancer.
    American journal of clinical oncology, 2004, Volume: 27, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C

2004
[Radiotherapy of carcinomas of the anal canal. Tenon Hospital experience].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2003, Volume: 7 Suppl 1

    Topics: Aged; Anal Canal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Ch

2003
[Orotate phosphoribosyl transferase in bladder cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:9

    Topics: Carcinoma, Transitional Cell; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Neoplasm Stagi

2004
FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder.
    Japanese journal of clinical oncology, 2004, Volume: 34, Issue:12

    Topics: Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bi

2004
A single institution experience with concurrent capecitabine and radiation therapy in weak and/or elderly patients with urothelial cancer.
    International journal of radiation oncology, biology, physics, 2005, Aug-01, Volume: 62, Issue:5

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma in Situ; Carcinoma

2005
Zosteriform metastatic transitional cell carcinoma.
    International journal of dermatology, 2005, Volume: 44, Issue:12

    Topics: Acyclovir; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Transitional

2005
Neoadjuvant chemotherapy enables R0 resection of locally advanced rectal cancer in a patient with a previously irradiated pelvis.
    The British journal of radiology, 2007, Volume: 80, Issue:956

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Trans

2007
Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.
    Cancer, 2008, May-15, Volume: 112, Issue:10

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C

2008
In vitro chemotherapy testing of transitional cell carcinoma.
    Investigative urology, 1980, Volume: 17, Issue:5

    Topics: Antineoplastic Agents; Bleomycin; Carcinoma, Transitional Cell; Cells, Cultured; Cisplatin; Cyclopho

1980
Efficacy and side effects of the regional arterial infusion of anti-cancer drugs combined with direct hemoperfusion in malignancies of the urinary tract.
    The Journal of urology, 1982, Volume: 128, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Bleomycin; Carcinoma, Transitional Cell; Charcoal; Doxorubicin; Female;

1982
[Effective cases of advanced endometrial and recurrent ovarian cancers treated with oral administration of UFT].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Tra

1984
[Clinical application of tegafur suppositories for bladder tumor].
    Hinyokika kiyo. Acta urologica Japonica, 1983, Volume: 29, Issue:8

    Topics: Adult; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Fluorouracil; Humans; Male; Mid

1983
Results and toxicity of the treatment of anal canal carcinoma by radiation therapy or radiation therapy and chemotherapy.
    Cancer, 1984, Nov-15, Volume: 54, Issue:10

    Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Car

1984
Regression of pulmonary metastases from cloacogenic carcinoma after cis-platinum/5-fluorouracil treatment.
    Journal of clinical gastroenterology, 1984, Volume: 6, Issue:3

    Topics: Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Transit

1984
[Chemotherapy of metastatic urothelial carcinoma. cis-Diamminedichloroplatinum combination chemotherapy for patients with decreased renal function].
    Hinyokika kiyo. Acta urologica Japonica, 1984, Volume: 30, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell;

1984
[Combination chemotherapy of advanced transitional cell carcinoma with cis-platinum, cyclophosphamide, adriamycin and 5-fluorouracil (CISCAF)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin

1984
Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil.
    Cancer chemotherapy and pharmacology, 1983, Volume: 11 Suppl

    Topics: Actuarial Analysis; Adenocarcinoma; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protoco

1983
The treatment of primary operable transitional cell cancer of the bladder without cystectomy. Preliminary report.
    International journal of clinical pharmacology, therapy, and toxicology, 1983, Volume: 21, Issue:11

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Doxorubicin; Fem

1983
Induction chemotherapy with cisplatin and cyclophosphamide and maintenance chemotherapy with doxorubicin and 5-FU in advanced urinary bladder tumors.
    Cancer treatment reports, 1983, Volume: 67, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Doxor

1983
Combination chemotherapy including adriamycin for advanced transitional cell carcinoma of the urinary tract.
    Cancer chemotherapy and pharmacology, 1983, Volume: 11 Suppl

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Transitional Ce

1983
Intravesical high dose 5-fluorouracil instillations combined with allopurinol--a therapeutic alternative in the treatment of multiple bladder tumors.
    The Journal of urology, 1984, Volume: 132, Issue:1

    Topics: Allopurinol; Carcinoma, Transitional Cell; Drug Therapy, Combination; Fluorouracil; Humans; Neoplasm

1984
The effect of chemotherapeutic agents on the ultrastructure of transitional cell carcinoma in tissue culture.
    Investigative urology, 1980, Volume: 17, Issue:4

    Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Nucleolus; Fluorouracil; Humans; In Vitro

1980
Conservative management of low grade neoplasms of the male urethra: a preliminary report.
    The Journal of urology, 1980, Volume: 123, Issue:2

    Topics: Adult; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Fluorouracil; Humans; Male; Middle Ag

1980
Transcatheter intraarterial infusion of chemotherapy in advanced bladder cancer.
    Cancer, 1982, Feb-15, Volume: 49, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Doxorubicin; Drug Thera

1982
[Chemotherapy of metastatic urothelial carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1982, Volume: 9, Issue:11

    Topics: Adenocarcinoma; Aged; Carcinoma, Transitional Cell; Cisplatin; Doxorubicin; Drug Therapy, Combinatio

1982
Chemotherapy of carcinoma of renal pelvis: preliminary report.
    Urology, 1981, Volume: 18, Issue:1

    Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto

1981
Combination chemotherapy with adriamycin and 5-fluorouracil in advanced bladder carcinoma.
    Clinical oncology, 1982, Volume: 8, Issue:2

    Topics: Aged; Carcinoma, Transitional Cell; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hu

1982
Response of metastatic cloacogenic carcinoma to treatment with semustine.
    Cancer, 1981, Dec-15, Volume: 48, Issue:12

    Topics: Anus Neoplasms; Carcinoma, Transitional Cell; Drug Administration Schedule; Female; Fluorouracil; Hu

1981
Phase II study of 5-fluorouracil and adriamycin in transitional cell carcinoma of the urinary tract.
    Cancer treatment reports, 1980, Volume: 64, Issue:1

    Topics: Adult; Aged; Carcinoma, Transitional Cell; Doxorubicin; Drug Evaluation; Drug Therapy, Combination;

1980
[A case of advanced cancer of the renal pelvis effectively treated by continuous infusion of 5-fluorouracil].
    Hinyokika kiyo. Acta urologica Japonica, 1994, Volume: 40, Issue:9

    Topics: Aged; Carcinoma, Transitional Cell; Combined Modality Therapy; Female; Fluorouracil; Humans; Infusio

1994
Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide.
    Cancer, 1994, Nov-01, Volume: 74, Issue:9

    Topics: Antineoplastic Agents; Base Sequence; Blotting, Northern; Carcinoma, Transitional Cell; Cisplatin; D

1994
Multimodal treatment of locally advanced transitional cell bladder carcinoma in elderly patients.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:7

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Tra

1994
Cancer of the anal canal: treatment with chemotherapy and low-dose radiation therapy.
    Radiology, 1994, Volume: 191, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Carcinoma,

1994
Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients.
    Cancer, 1994, Mar-15, Volume: 73, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neo

1994
Chemoradiation therapy for anal cancer: radiation plus continuous infusion of 5-fluorouracil with or without cisplatin.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1993, Volume: 27, Issue:3

    Topics: Anal Gland Neoplasms; Animals; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cisplatin; Co

1993
Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio

1993
Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line.
    Japanese journal of cancer research : Gann, 1995, Volume: 86, Issue:11

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette

1995
[Infiltrating cancer of the bladder: can radiochemotherapy be an alternative to cystectomy?].
    Journal d'urologie, 1996, Volume: 102, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast

1996
Transurethral resection and intra-arterial chemotherapy for muscle-invasive bladder cancer.
    International urology and nephrology, 1996, Volume: 28, Issue:2

    Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti

1996
[Outcome of simultaneous radiochemotherapy of anal carcinoma].
    Zentralblatt fur Chirurgie, 1997, Volume: 122, Issue:1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma,

1997
[Preoperative chemoradiation therapy for advanced rectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:14

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

1997
Radiotherapy alone or radiochemotherapy with platin derivatives following transurethral resection of the bladder. Organ preservation and survival after treatment of bladder cancer.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1998, Volume: 174, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplasti

1998
Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
    The Journal of urology, 1998, Volume: 160, Issue:2

    Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic

1998
[Intraarterial chemotherapy via reservoir system for far-advanced bladder and prostate cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:9

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

1998
[Treatment of infiltrating cancer of the bladder with cisplatin, fluorouracil, and concurrent radiotherapy: results of a pilot study].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 1998, Volume: 2 Suppl 1

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cel

1998
[Concurrent chemotherapy and hyperfractionated radiotherapy for non-operable carcinoma of the bladder].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 1998, Volume: 2 Suppl 1

    Topics: Aged; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiat

1998
Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:9

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Combined Moda

1997
The significance of dihydropyrimidine dehydrogenase (DPD) activity in bladder cancer.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Trans

2001
Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatment.
    Acta oncologica (Stockholm, Sweden), 2001, Volume: 40, Issue:5

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biological Availability; Bone Marrow; Carb

2001
Thymidine phosphorylase and dihydropyrimidine dehydrogenase in bladder cancer.
    Urologia internationalis, 2002, Volume: 68, Issue:2

    Topics: Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Dihydrouracil Dehydrogenase (NADP); Enzym

2002
Phase II study of adriamycin, 5-fluorouracil, levamisole, and irradiation in carcinoma of the bladder.
    Cancer treatment reports, 1979, Volume: 63, Issue:2

    Topics: Bone Marrow; Carcinoma, Transitional Cell; Doxorubicin; Drug Evaluation; Drug Therapy, Combination;

1979
A toxicity study of the treatment of T3 bladder tumours with a combination of radiotherapy and chemotherapy.
    British journal of urology, 1977, Volume: 49, Issue:7

    Topics: Adult; Aged; Carcinoma, Transitional Cell; Doxorubicin; Female; Fluorouracil; Humans; Male; Middle A

1977
Management of urinary bladder cancer.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1978, Oct-28, Volume: 54, Issue:18

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Fem

1978
Effectiveness of long-term chemotherapy and/or BCG on murine bladder cancer.
    National Cancer Institute monograph, 1978, Issue:49

    Topics: Animals; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Cyclophosphamide; Doxorub

1978
Combined surgery, radiotherapy and regional chemotherapy in carcinoma of the maxillary sinus.
    Auris, nasus, larynx, 1978, Volume: 5, Issue:1

    Topics: Bromodeoxyuridine; Carcinoma; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Fluorouracil;

1978
Use of arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation as a treatment for carcinoma of the prostate and bladder.
    American journal of surgery, 1975, Volume: 130, Issue:5

    Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Drug Administration Sc

1975
Doxorubicin hydrochloride, cyclophosphamide, and 5-fluorouracil combination in advanced prostate and transitional cell carcinoma.
    Urology, 1976, Volume: 8, Issue:5

    Topics: Acid Phosphatase; Adenocarcinoma; Aged; Carcinoma, Transitional Cell; Cyclophosphamide; Doxorubicin;

1976
Treatment of advanced bladder cancer with adriamycin and 5-fluorouracil.
    British journal of urology, 1976, Volume: 48, Issue:7

    Topics: Aged; Carcinoma, Transitional Cell; Doxorubicin; Drug Therapy, Combination; Evaluation Studies as To

1976
Bladder cancer in man. An update.
    Minnesota medicine, 1975, Volume: 58, Issue:3

    Topics: Carcinoma, Transitional Cell; Fluorouracil; Humans; Male; Prognosis; RNA Viruses; Urinary Bladder Ne

1975
Single and combination chemotherapy for primary murine bladder cancer.
    Cancer, 1975, Volume: 36, Issue:2

    Topics: Animals; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Dactinomycin; Disease Models, An

1975
Arterial infusion of 5-FU as a therapeutic adjunct in the treatment of advanced carcinoma of bladder and prostate.
    Virginia medical monthly, 1975, Volume: 102, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Female; Fluorou

1975
[Study of preventive effect of 1-hexylcarbamoyl-5-fluorouracil (HCFU) or combination of HCFU and 2.5-di-O-acetyl-D-glucaro (1-4) (6-3) dilactone (SLA) after preservative operation against bladder cancer].
    Hinyokika kiyo. Acta urologica Japonica, 1992, Volume: 38, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio

1992
Combined chemoradiation therapy for anal cancer. A report of 56 cases.
    Annals of surgery, 1992, Volume: 215, Issue:2

    Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols;

1992
[Sequential methotrexate and 5-fluorouracil, doxorubicin, and cisplatin for advanced urothelial cancer].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1992, Volume: 83, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1992
[Thymidylate synthase inhibition and concentration of 5-fluorouracil after administration of UFT in human uroepithelial carcinomas].
    Hinyokika kiyo. Acta urologica Japonica, 1991, Volume: 37, Issue:3

    Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto

1991
Complete response of a transitional cell carcinoma of the renal pelvis to leucovorin/5 fluorouracil chemotherapy.
    Australian and New Zealand journal of medicine, 1991, Volume: 21, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Female; Fluorouracil;

1991
Combined 5-fluorouracil and irradiation for transitional cell carcinoma of the urinary bladder.
    International journal of radiation oncology, biology, physics, 1990, Volume: 19, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystectomy;

1990
[Single drug chemotherapy with 5-FU oral administration of bladder cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:10

    Topics: Administration, Oral; Carcinoma, Transitional Cell; Fluorodeoxyuridylate; Fluorouracil; Humans; Male

1990
Treatment of advanced transitional cell carcinoma of the bladder with irradiation and concomitant 5-fluorouracil infusion.
    International journal of radiation oncology, biology, physics, 1990, Volume: 18, Issue:5

    Topics: Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Combined Modality Therapy; Female; Fluorourac

1990
[Sequential combination chemotherapy consisting of vincristine, peplomycin, methotrexate, cis-diamminedichloroplatinum (II), cytosine arabinoside and 5-fluorouracil, for advanced urothelial cancer].
    Hinyokika kiyo. Acta urologica Japonica, 1985, Volume: 31, Issue:7

    Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous

1985
Excellent response to cis-platinum-based chemotherapy in patients with recurrent or previously untreated advanced nasopharyngeal carcinoma.
    American journal of clinical oncology, 1988, Volume: 11, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carci

1988
Preoperative intra-arterial infusion chemotherapy for patients with bladder cancer.
    European urology, 1989, Volume: 16, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell;

1989
Radiotherapy for anal cancer: experience from 1979-1987.
    International journal of radiation oncology, biology, physics, 1989, Volume: 17, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anus Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Transitional Ce

1989
Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no. 8314.
    Journal of the National Cancer Institute, 1989, Jun-07, Volume: 81, Issue:11

    Topics: Anal Canal; Anus Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cobalt Radioisot

1989
Presurgery chemotherapy (CT) in locally advanced bladder carcinoma: a feasible and possibly effective approach.
    Medical oncology and tumor pharmacotherapy, 1989, Volume: 6, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin

1989
Low dose intermittent 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in poor risk patients with advanced transitional cell bladder cancer: a pilot study.
    Journal of chemotherapy (Florence, Italy), 1989, Volume: 1, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cyclophosphamide

1989
Combined preoperative neoadjuvant radiotherapy and chemotherapy for anal and rectal cancer.
    American journal of surgery, 1986, Volume: 151, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squ

1986
[Pathomorphosis of bladder cancer after endolymphatic polychemotherapy].
    Arkhiv patologii, 1986, Volume: 48, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Cancer,

1986
Feasibility of non-surgical definitive management of anal canal carcinoma.
    International journal of radiation oncology, biology, physics, 1987, Volume: 13, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carc

1987
[Function-preserving treatment of anal cancer using simultaneous radio- and chemotherapy].
    Deutsche medizinische Wochenschrift (1946), 1987, Jul-31, Volume: 112, Issue:31-32

    Topics: Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Carcinoma,

1987
Adjuvant chemotherapy for invasive bladder cancer.
    Cancer chemotherapy and pharmacology, 1987, Volume: 20 Suppl

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Transitional Cell; Cispl

1987
[Clinical studies of the treatment of bladder tumor and its effects--experience in 86 cases].
    Hinyokika kiyo. Acta urologica Japonica, 1988, Volume: 34, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Tr

1988
[Combination transurethral resection and systematic chemotherapy as primary treatment of infiltrating bladder tumors (pT2-pT4 NxM0)].
    Journal d'urologie, 1988, Volume: 94, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitio

1988
[Cutaneous metastasis of a cloacogenic tumor].
    Medicina cutanea ibero-latino-americana, 1987, Volume: 15, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Transitional Cell;

1987
Pre surgery chemotherapy in bladder cancer.
    Progress in clinical and biological research, 1988, Volume: 260

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combined Mo

1988
Transitional cell carcinoma of the urinary bladder: histologic clearance with combined 5-FU chemotherapy and radiation therapy. Preliminary results of a bladder-preservation study.
    Radiology, 1988, Volume: 167, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Combined Modality Therapy; Female; Flu

1988
[An autopsy case of untreated bladder cancer].
    Hinyokika kiyo. Acta urologica Japonica, 1987, Volume: 33, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Doxorubicin

1987
Combination chemotherapy with fluorouracil, adriamycin, cis-platinum and VM-26 in advanced transitional cell carcinoma of the urinary tract.
    European journal of cancer & clinical oncology, 1986, Volume: 22, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin

1986
[Combined therapy with 5-fluorouracil, doxorubicin, cis-diamminedichloroplatinum on advanced urothelial cancer].
    Nihon Gan Chiryo Gakkai shi, 1987, Feb-20, Volume: 22, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin

1987
[A case of complete remission of distant metastases of a renal pelvic tumor by combination chemotherapy with mitomycin, cyclophosphamide and 5-fluorouracil].
    Hinyokika kiyo. Acta urologica Japonica, 1986, Volume: 32, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cyclophosphamide; Fema

1986
[Therapeutic experiences of cis-diamminedichloroplatinum, adriamycin and 5-fluorouracil combination chemotherapy in advanced urothelial cancer, with special reference to adjuvant chemotherapy in invasive urothelial cancer].
    Hinyokika kiyo. Acta urologica Japonica, 1986, Volume: 32, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Transitional Cell;

1986
Treatment of advanced bladder carcinoma with irradiation and concomitant 5-fluorouracil infusion.
    Cancer, 1987, Feb-15, Volume: 59, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitio

1987
High-dose intensity systemic therapy of metastatic bladder cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Circadian Rhythm

1987
[Chemosensitivity test for bladder cancer in a nude-mice experimental system].
    Hinyokika kiyo. Acta urologica Japonica, 1986, Volume: 32, Issue:12

    Topics: Aged; Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Line; Cisplatin; Colony-For

1986
[Chemotherapy for advanced bladder cancer: clinical evaluation of chemotherapy for locally advanced or metastatic bladder cancer and adjuvant chemotherapy for deeply invasive bladder cancer following radical cystectomy].
    Hinyokika kiyo. Acta urologica Japonica, 1985, Volume: 31, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitio

1985
Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy.
    The American journal of medicine, 1985, Volume: 78, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cel

1985
[Thermotherapy for cancer of the urinary bladder in combination with tegafur suppository and picibanil--concentrations of tegafur in the serum and tissues in bladder carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:5

    Topics: Adult; Aged; Biological Products; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Female; Fl

1985
Neoplasia of the equine urinary bladder as a cause of hematuria.
    Journal of the American Veterinary Medical Association, 1985, Jun-15, Volume: 186, Issue:12

    Topics: Animals; Biopsy; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cystoscopy; Female; Fibroma

1985
Therapeutic experience of advanced urothelial tract tumors.
    Hinyokika kiyo. Acta urologica Japonica, 1985, Volume: 31, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combined Mo

1985
[Effects of intravesical instillation of antitumor agents on bladder cancer].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1972, Volume: 63, Issue:7

    Topics: Aged; Carcinoma, Papillary; Carcinoma, Transitional Cell; Female; Fluorouracil; Humans; Injections;

1972
Primary transitional cell carcinoma of the prostate.
    The Journal of urology, 1973, Volume: 110, Issue:2

    Topics: Aged; Alkaline Phosphatase; Blood Urea Nitrogen; Carcinoma, Transitional Cell; Diethylstilbestrol; F

1973
Effect of chemotherapeutic agents on bladder cancer: a new animal model.
    Surgical forum, 1973, Volume: 24

    Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Cyclophosphamide; Dactinomycin; Diamin

1973
Scan evidence of decrease in size of intrahepatic tumors after chemotherapy. A case report.
    Gastroenterology, 1974, Volume: 67, Issue:3

    Topics: Adult; Aged; Carcinoma, Transitional Cell; Cecal Neoplasms; Doxorubicin; Female; Fluorouracil; Human

1974
Distant metastases from beta-naphthylamine induced vesical tumors in dogs.
    The Journal of urology, 1969, Volume: 102, Issue:5

    Topics: Animals; Carcinogens; Carcinoma, Transitional Cell; Dogs; Female; Fluorouracil; Lung Neoplasms; Naph

1969